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Abstract Graft-versus-host disease (GVHD) remains a
major limitation of allogeneic hematopoietic cell trans-
plantation (allo-HCT). Despite major advances in the
understanding of GVHD pathogenesis, standard GVHD
prophylaxis regimens continue to be based on the com-
bination of a calcineurin inhibitor with an antimetabolite,
while first line treatments still rely on high-dose cortico-
steroids. Further, no second line treatment has emerged
thus far in acute or chronic GVHD patients who failed to
respond with corticosteroid treatment. After briefly
reviewing current standards of GVHD prevention and
treatment, this article will discuss recent approaches that
might change GVHD prophylaxis/treatment for decades
to come, with a special focus on recently developed
immunoregulatory strategies based on infusion of mesen-
chymal stromal or regulatory T-cells, or injection of low-
dose interleukin-2.
Keywords Allogeneic hematopoietic cell transplantation .
Graft-versus-host disease . GVHD .Mesenchymal stromal
cells . MSC . Regulatory T-cells . Treg . IL-2
Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) re-
mains the best treatment option for selected patients with
severe primary immune-deficiencies, hemoglobinopathies, se-
vere aplastic anemia, or hematological malignancies [1]. In
the latter case, its anti-tumoral efficacy depends not only on
high-dose (myeloablative conditioning) or lower-dose
(reduced-intensity or nonmyeloablative conditioning)
chemo/radiotherapy given during the conditioning regimen,
but also on immune-mediated graft-versus-tumor effects [2].
Although mechanisms of graft-versus-tumor effects are not
yet fully elucidated, destruction of recipient tumor cells by
donor T-cells contained in the graft (and directed against
minor or major histocompatibility antigen mismatches be-
tween donor and recipient or against tumor-associated anti-
gens) is thought to play a primordial role [3–6]. Unfortunately,
donor T-cells contained in the graft can also target healthy
recipient tissues and cause graft-versus-host disease (GVHD),
a potentially life-threatening complication of allo-HCT [7].
GVHD has been historically separated into two syndromes:
acute GVHD, occurring within 100 days after transplantation,
and chronic GVHD developing thereafter [8]. However,
GVHD with characteristics of the chronic form can occur
before day 100 after allo-HCT, while GVHD with character-
istics of the acute form may occur beyond day 100, particu-
larly in patients transplanted after nonmyeloablative condi-
tioning and in those given donor lymphocyte infusions. These
observations are the basis of a new GVHD classification (NIH
classification) that recognized two categories of GVHD: acute
GVHD, defined as GVHD without signs consistent with
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chronic GVHD and comprising classic acute GVHD occur-
ring before day 100, and late acute GVHD occurring beyond
day 100; and chronic GVHD including classic chronic
GVHD, defined as chronic GVHD without signs of acute
GVHD, and overlap syndrome, in which features of both acute
and chronic GVHD coexist [9]. Interestingly, despite a strong
association between GVHD and graft-versus-tumor effects
[10–12], only milder forms of acute GVHD and NIH-
defined chronic GVHD have been associated with improved
survival, because of a strong association between severe forms
of GVHD and nonrelapse mortality [13, 14]. In this article, we
will review current practice and perspectives in GVHD pre-




The most efficient way to prevent GVHD consists of in vitro
T-cell depletion of the graft. Based on data observed in murine
experiments byDicke et al. in the late 1960 s [15], hundreds of
T-cell depleted allogeneic bone marrow transplantations were
performed in the 1980 s [16]. Methods of T-cell depletion
were mainly based on negative selection techniques (by phys-
ical separation or antibody-based purging). For example, a
number of groups of investigators performed T-cell depletion
by combining murine monoclonal antibodies and rabbit com-
plement. This technique allowed a T-cell reduction of 2–3 logs
and a low incidence of grade II–IV acute (10–20 %) GVHD,
even without any postgrafting immunosuppression [17–19].
However, this benefit was offset by higher incidences of graft
rejection/failure, infection (including post-transplant lympho-
proliferative disease), and leukemia relapse [16, 19]. In the
1990s, techniques of positive immune-magnetic selection of
hematopoietic stem cells (CD34+ cells) were developed con-
comitantly to the use of G-CSF mobilized peripheral blood
stem cells (PBSC) as allogeneic stem cell source. This method
allows for a 3–4 log T-and B-cell depletion and a significant
reduction in the incidence of acute and chronic GVHD, with-
out increasing the risk of post-transplant lymphoproliferative
disease (probably due to concomitant B-cell depletion)
[20–22, 23•]. This approach allowed doctors to perform suc-
cessful allo-HCT across HLA barriers by infusing megadoses
of HLA-haploidentical CD34+ selected cells [24]. In the
HLA-identical setting, although a recent study suggested
similar leukemia-free survival but less chronic GVHD in
patients given CD34-selected PBSC in comparison to
unmanipulated PBSC [23•], large randomized studies
are needed before this approach may become a standard
of care for GVHD prophylaxis.
Thus, despite progress in T-cell depletion methods, the
current standard of care for GVHD prevention in patients
receiving grafts from HLA-matched donors in most transplant
centers remains the combination of a calcineurin inhibitor
(cyclosporine or tacrolimus) and an antimetabolite [short
methotrexate in case of myeloablative transplantation or my-
cophenolate mofetil (MMF) in case of reduced-intensity or
nonmyeloablative transplantation, or in the setting of cord
blood transplantation] [25–31]. Although these combinations
have been relatively successful at preventing the most severe
forms of acute GVHD, they failed to prevent the development
of moderate/severe chronic GVHD in a large proportion of
patients, and particularly in those given PBSC [32], and/or in
those given grafts from unrelated donors [33].
In order to decrease the incidence of moderate/severe
chronic GVHD in patients at high risk for this complication,
a number of groups have added anti-thymocyte globulin
(ATG) to standard GVHD prophylaxis regimens. Recent stud-
ies have suggested that the addition of ATG successfully
decreased the incidence of chronic GVHD without increasing
the risk of relapse both in patients receiving grafts from HLA-
matched unrelated donors after myeloablative conditioning
and given 60 mg/kg ATG Fresenius® or 4.5–6.0 mg/kg ATG
Thymoglobulin® [34–36, 37••], and in those receiving PBSC
after reduced-intensity conditioning and given ≤5 mg/kg of
ATG Thymoglobulin® [38]. In contrast, the use of ≥10 mg/kg
ATG Thymoglobulin® was associated with higher risks of
disease relapse and infections in patients transplanted after
reduced-intensity conditioning [39–41].
New Pharmacological Approaches
A number of new pharmacological approaches for GVHD
prevention are being evaluated. These include in vivo T-cell
depletion with alemtuzumab, or the post-transplant use of
azacitidine, sirolimus, cyclophosphamide, anti-TNF agents,
or bortezomib.
In vivo T-cell depletion with alemtuzumab, a humanized
anti-CD52 IgG1 monoclonal antibody with broad
lymphocyte-depleting properties, has been extensively stud-
ied in patients given grafts after reduced-intensity condition-
ing, generally combined with cyclosporine [42]. Administra-
tion of 100 mg alemtuzumab during the conditioning regimen
was very successful at preventing acute and chronic GVHD,
but was also associated with higher risks of infection and
relapse in patients transplanted for hematological malignan-
cies [14, 43, 44]. Current efforts to prevent relapse with this
approach are focusing on decreasing the dose of
alemtuzumab, or administering pre-emptive DLI in patients
with evidence of poor donor chimerism of minimal residual
disease [45, 46].
Another recent approach consisted at administering the
hypomethylating agent azacitidine post-transplantation. Post-
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transplant azacitidine increased regulatory T-cell (Treg, vide
infra) numbers, and thus potentially prevented GVHD, and
also induced a cytotoxic CD8+ T-cell response to several
tumor antigens including WT1 [47•].
Sirolimus (rapamycin) is a mTOR inhibitor that prevents
activation of T-cells by inhibiting their response to IL-2 with-
out affecting Tregs that respond to IL-2 stimulation mainly by
the Stat-5 pathway [48]. Based on encouraging data observed
in phase II studies [49, 50], the Blood and Marrow Transplant
Clinical Trials Network conducted a large randomized study
(n=304) comparing postgrafting immunosuppression with ta-
crolimus and methotrexate versus tacrolimus plus sirolimus in
patients given grafts from HLA-identical siblings after TBI-
based myeloablative conditioning. No difference in 114-day
acute GVHD-free survival (primary endpoint) was observed,
while relapse, nonrelapse mortality and progression-free sur-
vival were also similar in the two arms [51].
Taking advantage of the observations that cyclophospha-
mide is highly cytotoxic to proliferating T-cells but spares
resting T-cells and hematopoietic stem cells, the John Hopkins
group investigated post-transplant administration of cyclo-
phosphamide as sole immunosuppressive treatment in patients
given bone marrow from HLA-matched donors or combined
with tacrolimus and MMF administration in those given
HLA-haploidentical grafts. Administration of cyclophospha-
mide (50 mg/kg) on days +3 and +4 after transplantation
allowed a low incidence of each grade III–IV acute (10 %)
and chronic (10%) GVHD in patient given bonemarrow from
HLA-matched donors [52], while administration of cyclo-
phosphamide (50 mg/kg) on day +3 (with or without a second
dose on day +4) combined with tacrolimus and mycopheno-
late mofetil started 1 day after cyclophosphamide administra-
tion also produced a low incidence of grade III–IVacute (6 %)
and chronic (25 %) GVHD in patients receiving bone marrow
from HLA-haploidentical donors [53]. However, given that
post-transplant cyclophosphamide might also kill donor T-
cells involved in graft-versus-tumor effects, the impact of
post-transplant cyclophosphamide on the relapse risk needs
to be further assessed.
TNF-α plays an important role in the initiation of GVHD
[54•]. Further, following myeloablative and even
nonmyeloablative conditioning regimens, the magnitude of
change in the TNF-receptor-1 (TNFR1; a good surrogate for
TNF-α) ratio (day +7 after transplantation/pretransplantation
baseline values) has been correlated with later occurrence of
acute GVHD [55, 56]. These observations prompted the de-
velopment of clinical studies aimed at assessing the impact of
TNF-α inhibition on GVHD prevention [57, 58]. Unfortu-
nately, administration of the TNF-α inhibitors infliximab
(10 mg/kg one day prior to conditioning and then on days 0,
+7, +14, +28, and +42) or etanercept (25 mg twice weekly
from start of conditioning to day +56) in addition to standard
GVHD prophylaxis failed to prevent acute GVHD [57, 58].
Finally, based on extensive murine experiments [59], the
proteasome inhibitor bortezomib (on days 1, 4 and 7 after allo-
HCT) has been assessed in combination with tacrolimus and
methotrexate as GVHD prophylaxis in 1–2/10 HLA-
mismatched unrelated graft recipients in a phase I–II study
including 45 patients. Indeed, bortezomib immunomodulatory
properties include selective depletion of proliferating
alloreactive T-cells while sparing Tregs, and inhibition
of antigen-presenting cell activation. Incidences of both
grade II–IV (22 %) and chronic (29 %) GVHD were
very encouraging [60].
Taken together, these studies suggest that a combination of
tacrolimus and sirolimus might be equivalent to standard
tacrolimus plus methotrexate in patients given TBI-based
conditioning, while in vivo T-cell depletion with alemtuzumab
as well as post-transplant azacitidine, cyclophosphamide or
bortezomib are promising approaches that should be further
investigated in multicenter randomized studies.
New Cellular Approaches
During the last decade, important advances have been made
regarding our knowledge of immunoregulatory cells such as
mesenchymal stromal cells (MSC) or Treg. MSC are
multipotent progenitors that can found within the bone mar-
row, but also within several connective tissues such as adipose
tissue, fetal membranes and the umbilical cord [61, 62, 63•].
Minimal criteria for MSC definition according to the Interna-
tional Society for Cellular Therapy (ISCT) include: 1) plastic
adherence when maintained in standard culture conditions; 2)
expression of CD105, CD73 and CD90, and lack of expres-
sion of CD45, CD34, CD14 or CD11b, CD79alpha or CD19
and HLA-DR surface molecules; and 3) ability to differentiate
into osteoblasts, adipocytes and chondrocytes in vitro [64].
MSC have important immunoregulatory properties both
in vitro and in vivo, such as inhibition of T-cell proliferation
and dendritic cell differentiation, and prolongation of skin or
cardiac transplant survival [63•, 65, 66]. Our understanding on
how MSC impact immune cells has considerably improved
over the last decade [63•, 66]. As a result of these studies,
MSC are now considered to respond to their immediate envi-
ronment and adapt their response accordingly through the
release of soluble factors, such as prostaglandin E2 (PGE2),
IL-10, transforming growth factor beta (TGF-β), nitric oxide
(NO), heme oxygenase-1 (HO-1), HLA-G5, hepatocyte
growth factor (HGF), bone morphogenetic protein 2
(BMP2), or galectin-1, through induction of indoleamine 2,3
dioxygenase (IDO), and/or through cell contact signaling via
Notch and CD95/Fas [63•, 66–68]. Further, context-
dependent modification of T-helper (Th)1/Th2 ratio has been
shown in several inflammatory disease models [69], while a
number of additional studies have demonstrated the ability for
MSC to promote/expand Tregs in vitro and in vivo (mainly
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through TGF-β and IDO) and to inhibit the differentiation of
pro-inflammatory Th-17 cells (through PGE2) [70]. Finally,
In addition to having a plethora of immunoregulatory proper-
ties, MSC are hypoimmunogenic, allowing transfer across
HLA barriers [63•], which is mandatory for “off-the-shelf”
cellular therapy.
A number of studies have assessed the ability of MSC infu-
sion at preventing GVHD in various murine models of GVHD
[71–76], in humanized murine models of xenogeneic GVHD
[77, 78], as well as in a preclinical canine model of GVHD [79].
Taken together, these studies suggested that a single injection of
(non-activated) MSC given on day 0 failed to prevent GVHD in
most models [71, 73, 77, 78], while a single infusion of activated
MSC on day 0 [73], or repeated MSC injections at the time of
and after transplantation showed clinical benefit in some [72, 76,
77] but not all [74, 75, 78] studies, depending on the GVHD
model, the timing ofMSC infusion, the dose ofMSC infused, as
well as the origin of MSC. However, repeated MSC injection
failed to prevent lethal GVHD in a pre-clinical canine model of
dog leukocyte antigen-haploidentical transplantation [79].
A number of small clinical studies have studied the impact
of MSC infusion at the time of allo-HCT on engraftment and
GVHD [80–85]. These pilot studies suggested that MSC co-
transplantation did not prevent graft rejection in the setting of
T-cell repleted transplantation [83, 84], while it might do so in
the setting of HLA-haploidentical T-cell depleted allo-HCT
[81]. Interestingly, three studies observed a lower incidence of
acute GVHD in patients co-transplanted with MSC compared
to historical [83, 84] or concurrent [82] controls, suggesting
that MSCmight help reducing GVHD. However, these results
should be taken with caution given the small number of
patients included in these pilot studies. Prospective, multicen-
ter, double-blind randomized studies are ongoing in order to
assess more definitely the impact of MSC co-transplantation
on GVHD (ClinicalTrials.gov Identifier: NCT01045382).
Treg play a critical role in the maintenance of tolerance to
self-antigens [86•]. Their development and function requires
the transcription factor FoxP3. In the last decade, much atten-
tion has been paid to the potential role of Tregs after allo-HCT.
In murine experimental GVHDmodels, administration of high
doses of Tregs (conventional T cells /Tregs ratio of 1 or 2) at the
time of transplantation prevented acute GVHD without appar-
ently impairing graft-versus-tumor effects [87–89]. Similarly, a
number of studies demonstrated that Treg infusion was able to
prevent xenogeneic GVHD in humanized mice [90, 91]. In
humans, Di Ianni et al. investigated the ability of Treg to allow
for infusion of relatively large numbers of conventional T-cells
in the HLA-haploidentical setting [92••]. The trial included 28
high-risk adult patients with advanced hematological malig-
nancies. Patients received a myeloablative conditioning regi-
men, followed by the infusion of freshly isolated donor CD25+
Tregs (2x10
6/kg, enriched using a two-step procedure, simulta-
neous CD8 and CD19 depletion followed by CD25-positive
selection) on day-4 before transplantation. Following this pre-
conditioning, patients were transplanted on day 0 with mega-
doses of CD34+ hematopoietic stem cells to reconstitute the
bone marrow and conventional T-cells (0.5–4.0×106 cells/kg)
to reconstitute the immune system. Immune reconstitution was
prompt with CD4+ and CD8+ donor T-cell counts reaching the
normal range within 2–3 months. Most remarkably, of the 28
patients only two developed at least grade II acute GVHD and
none chronic GVHD, despite not using postgrafting immuno-
suppression and a relatively low Treg purity (80+/−22 %
FoxP3-positive cells [93]). In addition, Brunstein et al.
investigated the ability of umbilical cord blood-derived
Tregs (0.1–30×10
5 Tregs/kg) to decrease the incidence of
acute GVHD in 23 adult patients given double umbilical cord
blood transplantation [94]. Tregs were obtained from a third
cord blood unit that was 4–6/6 HLA-matched with the recip-
ient and expanded in vitro over 18 days with anti-CD3/anti-
CD28 monoclonal antibody-coated Dynabeads® and 300 IU/
mL Il-2. Importantly, the authors observed a lower incidence of
grade II–IVacute GVHD in patients given Tregs than in a group
of similarly treated 108 historical patients not given Tregs (43%
versus 61 %, P=0.05). Although very promising, the results
should be confirmed in prospective randomized studies.
Treatment of Acute GVHD
Current Practice
The standard of care for first line treatment of grade II–IVacute
GVHD consists of methylprednisolone (or prednisone) starting
at 2 mg/kg for 7 days with slow subsequent tapering according
to GVHD response [31, 95, 96••]. Nonabsorbable oral corti-
costeroids (budesonide, 9 mg/day) are often added to systemic
corticosteroids in patients with gastrointestinal acute GVHD
[97]. Methylprednisolone produces complete responses in 25
to 69 % (53 % in the largest study reported thus far [98]) of
patients with grade II–IVacute GVHD [99–102]. Interestingly,
one retrospective study suggested that initial treatment with
1 mg/kg methylprednisolone did not compromise disease con-
trol or mortality in patients with grade II acute GVHD [101].
Outcomes for patients with corticosteroid-refractory acute
GVHD are dismal, and unfortunately, there is no standard of




Many attempts at intensifying the front line treatment for
grade II–IV acute GVHD failed. Specifically, the addition of
horse ATG, antibodies against IL-2 [basiliximab, daclizumab
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or denileukin diftitox (denileukin)], antibodies against
TNF-α (etanercept or infliximab), or pentostatin to
(methyl)prednisolone failed to improve response rates,
and were often associated with higher nonrelapse mortal-
ity [104–108]. A phase II four-arm randomized study was
recently conducted with the aim of identifying the most
promising agent in addition to standard methylpredniso-
lone for initial therapy for grade II–IV GVHD [109].
Patients were randomized to receive 2 mg/kg methylpred-
nisolone per day plus etanercept, MMF, denileukin
diftitox, or pentostatin. Day 28 complete response rate
was the highest with MMF (60 %). Based on this study,
the BMT-CTN conducted a multi-center, randomized,
double-blind phase III study comparing corticosteroids
plus placebo versus corticosteroids plus MMF as initial
treatment for acute GVHD [110]. Unfortunately, 56-day
GVHD-free survival (primary endpoint) and 6-month sur-
vival were similar in the two arms.
In an attempt at avoiding morbidity associated with high
doses of corticosteroids, Pidala et al. assessed the ability of
sirolimus as initial treatment for grade I (n=4), II (n=24), or III
(n=4) acute GVHD [111]. Sixteen of 32 patients (50 %)
achieved sustained, complete resolution of acute GVHD, a
rate similar to what was observed in matched historical con-
trols treated with standard 1 mg/kg steroids, suggesting that
sirolimus had comparable activity to that of high-dose
glucocorticoids in the primary therapy of grade I–III
acute GVHD. While encouraging, these results should
be confirmed in prospective randomized trials before
sirolimus could become a standard of care for initial
treatment of moderate acute GVHD.
Second Line Treatment
Antimetabolites (mycophenolate mofetil or methotrexate), ex-
tracorporeal photopheresis, antibodies against IL-2
(basiliximab, daclizumab, inolimomab or denileukin diftitox
(denileukin)), antibodies against TNF-α (etanercept or
infliximab), alemtuzumab and ATG have been assessed as
second line therapy for steroid-refractory acute GVHD (nicely
reviewed in reference [96••]). Combining data from 25 clini-
cal studies, 6-month overall survival from initiation of second
line therapy (a good surrogate for GVHD response) ranged
from 0 to 86 % (weighted average 6-month survival of 49 %),
without evidence that any of these treatments were better or
worse than another [96••]. This was confirmed by a single-
center retrospective study (n=93) showing similar outcomes
in patients with steroid-refractory acute GVHD treated
with mycophenolate mofetil, versus inolimomab, or
etanercept [112]. In contrast, a multicenter comparative
analysis suggested better survival for patients with
corticosteroid-refractory grade II acute GVHD treated
by extracorporeal photopheresis compared to those treat-
ed by anticytokine therapy [113].
New Cellular Approaches
Currently, cellular approaches for acute GVHD treatment
consist primarily of MSC infusion, although a few patients
with steroid-refractory acute GVHD have been treated with
(in vitro expanded) Tregs on a compassionate basis by Edinger
et al [114]., and in a patient with grade IV acute GVHD by
Trzonkowski et al [115]..
First Line Treatment
A phase II randomized multicenter study has evaluated two
different doses of MSC (Prochymal®, Osiris Therapeutics,
Columbia, MD) given in combination with standard methyl-
prednisolone for the initial therapy for acute GVHD [116].
Thirty-two adult patients with grade II (n=21), grade III (n=8)
or grade IV (n=3) acute GVHD were randomized to receive,
in addition to standard corticosteroids, two doses of either two
or eight million MSC/kg each. The first MSC infusion was
given within the 48 hr following diagnosis of grade II–IV
acute GVHD, and the second 3 days later. Ninety-four percent
of patients achieved complete (77 %) or partial (16 %) re-
sponses. Interestingly, the response rates were comparable in
patients given two or eight million MSC/kg. Based on these
encouraging results, a randomized, multicenter, phase III trial
compared 2×106 MSC/kg (Prochymal®) versus placebo in
addition to standard corticosteroid therapy as primary treat-
ment for 184 patients with grade II–IV acute GVHD
(ClinicalTrials.gov: NCT00562497). Although the results of
the final analysis are not yet published in a peer-reviewed
journal, Osiris reported that the trial failed to reach the primary
endpoint of durable complete response lasting ≥ 28 days
without any increase in corticosteroid dose nor second line
therapy and survival of ≥ 90 days [117].
Second Line Treatment
The use of MSC as treatment for steroid-refractory acute
GVHD was pioneered by Le Blanc et al. in 2004 [118]. Based
on the impressive impact of MSC in a child with steroid-
refractory grade IV acute GVHD, the Developmental Com-
mittee of the European Group for Blood and Marrow Trans-
plantation developed a phase II study assessing MSC therapy
in patients with steroid-refractory acute GVHD [119]. The
study included 55 patients with steroid-refractory grades II
(n=5), III (n=25) or IV (n=25) acute GVHD (Table 1).
Twenty-seven patients received one, 22 two, 4 three, 1 four
and 1 five MSC infusions (total of 92 MSC infusions). MSC
donors were either HLA-identical siblings (n=5), HLA-
haploidentical relatives (n=18), or third-party HLA-
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mismatched individuals (n=69), and the median dose of MSC
infused was 1.4 (range 0.4–9) x 106 MSC/kg. No side effects
were seen afterMSC infusions. Among the 55 patients, 30 had
complete and nine had partial responses. Median time from
MSC infusion to complete response was 18 (range, 3–63)
days, and responses were more frequently observed in chil-
dren than in adults. Following this report, a number of phase II
studies assessed the impact MSC in patients with steroid-
refractory acute GVHD (Table 1) [120–122]. While the
majority of these studies suggested efficacy of MSC
therapy, it remains to be demonstrated whether MSC
infusion provides better results than other second line
treatments for acute GVHD.
In an attempt at answering this question, the potential role
of MSC (Prochymal®) was evaluated in addition to standard
of care, including institutionally selected second line treat-
ment, in a randomized (2:1) multicentre trial in 244 patients
with steroid-refractory grade II–IV gastrointestinal (n=179),
skin (n= 144), and/or l iver (n= 61) acute GVHD
(ClinicalTrials.gov: NCT00366145). Patients received eight
infusions of placebo or 2×106 MSC/kg each over 4 weeks,
with an additional four infusions administered weekly after
day 28 in patients who had partial responses. Although the
study was completed in 2009, results have been published
only in abstract form thus far [123]. Unexpectedly, the study
did not observe a significant difference in the rate of overall
complete and durable (≥28 days) responses between the two
groups [primary endpoint; 35 in the MSC versus 30 in the
placebo groups (P=0.3)]. Incidence of relapse, infection, and
toxicities were also comparable in the MSC and placebo arms.
Potential explanations for the discrepancies between phase
II studies and the Prochymal® randomized study might be due
to differences in immunoregulatory properties between
Prochymal and “EBMT” MSC products [124]. Another po-
tential explanation could be that addingMSC to other efficient
second line therapy for acute GVHD failed to further improve
GVHD responses (indeed the response rates in the sec-
ond line plus placebo arm of the Prochymal study were
as high as 77 % and 68 % for skin and gastrointestinal
GVHD, respectively [123]).
Treatment of Chronic GVHD
Current Practice
Mild chronic GVHD is generally managed by topical treat-
ments. In contrast, first line treatment for moderate/severe
forms of chronic GVHD is generally based on corticosteroids,
often combined with cyclosporine or tacrolimus [125]. Unfor-
tunately, with these regimens only 20–50 % of patients
achieve complete resolution of GVHD and withdrawal of all
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term corticosteroid treatment causes numerous complications
such as infections, diabetes, myopathy, avascular necrosis,
osteoporosis, weight gain with changes in body habitus, cat-
aracts, and emotional lability. These observations led Martin
et al. to assess the addition of MMF to standard initial treat-
ment of chronic GVHD in a double-blind multicenter study
[126]. The study, unfortunately, did not demonstrate any ben-
efit of adding MMF, with a trend for higher risk of death in
patients given MMF (HR 1.9, 95 % CI:0.9–4.3).
E v e n t h o u gh s e v e r a l immuno s u p p r e s s i v e /
immunomodulating approaches have demonstrated therapeu-
tic activity in steroid-refractory chronic GVHD, the prognosis
of patients with such GVHD remains unsatisfactory with 2-
year survival ranging from 41 to 85 % with salvage therapy
[128–130]. There is no standard second line treatment for
steroid-refractory chronic GVHD and the “trial-and-error”
approach has remained the usual way to identify the drug
effective in the individual patient [130]. Second line treat-
ments include immunosuppressors (such as mycophenolate
mofetil, methotrexate, alemtuzumab), immunomodulating ap-
proaches [such as photopheresis, mTOR inhibition (sirolimus
or everolimus), thalidomide], thoraco-abdominal irradiation,
antifibrotic agents (imatinib, nilotinib), and rituximab [130].
New Pharmacological Approaches
As mentioned above, Tregs play a critical role in the
maintenance of tolerance to self-antigens [86•]. Indeed,
absence of Tregs causes fatal autoimmunity in mice and
humans [131, 132], while deficits in Treg function/
number have been observed in various autoimmune/
inflammatory disorders [86•, 133], as well as in GVHD
[134, 135]. Interleukin-2 (IL-2) is the critical cytokine
regulating Treg homeostasis [136, 137]. Following allo-
HCT (and particularly in patients with chronic GVHD),
there are high amounts of IL-7 and IL-15 that activate
conventional CD4+ T-cells [138, 139, 140••], combined
with a relative deficit of IL-2 favoring Treg apoptosis
[140••]. These observations prompted Koreth et al. to
conduct a phase 1 dose-escalation study aimed at deter-
mining the maximum tolerated dose of daily low-dose
subcutaneous IL-2 in patients with steroid-refractory
chronic GVHD [141]. Twenty-nine patients were includ-
ed, and the maximum tolerated dose of IL-2 was 1×106
IU/m2. Remarkably, 12 of 23 evaluable patients achieved
an objective partial response during the 8 weeks of IL-2
treatment. Further, IL-2 therapy improved Treg homeo-
stasis by increasing Treg proliferation, Treg resistance to
apoptosis, and Treg thymic export [140••]. Based on
these promising results, low-dose (1×106 IU/m2/day)
IL-2 is currently being assessed in patients with
steroid-refractory chronic GVHD in a phase II study
(ClinicalTrials.gov Identifier: NCT01366092).
New Cellular Approaches
There are few studies published thus far on the impact ofMSC
infusion in patients with steroid-refractory chronic GVHD.
Zhou et al. reported data from four patients with severe
sclerodermic chronic GVHD who were given MSC injected
directly into the bone marrow at total doses of 1–2×107 cells
for four to eight infusions within a 22–52 day period [142].
Following MSC infusions, the doses of immunosuppressive
medications were tapered significantly, while GVHD symp-
toms gradually improved in all four patients. More recently,
Weng et al. assessed the impact of i.v. MSC infusions in 19
patients with steroid-refractory chronic GVHD [143]. Patients
received a median of two (range, one to five) MSC infusions
given approximately 6 months apart at a median dose of 0.6
(range, 0.2–1.4) x 106 MSC/Kg. Fourteen of the 19 patients
achieved partial (n=10) or complete (n=4) responses.
Two-year survival rate from the first MSC infusion was
78 %. These two reports might serve as the basis for
prospective, double-blind, randomized studies assessing
the impact of MSC infusions in patients with steroid-
refractory chronic GVHD.
Although Treg homeostasis after allo-HCT is not fully
understood, it has been demonstrated that even in younger
patients, thymic generation of Tregs was minimal while Tregs
reconstituted by peripheral expansion of mature Tregs present
in the graft and exhibited a predominantly activated/memory
phenotype [144]. This was particularly true in older patients
given grafts after nonmyeloablative conditioning [145, 146].
Further, it has been observed that Tregs from patients with
extensive GVHD had low telomerase activity, thus restricting
their proliferative capacities [134], and were more susceptible
to apoptosis due to a higher expression of Bim and CD95 and
a lower expression of Bcl-2, stressing the interest for admin-
istering fresh Treg as GVHD therapy. These observations are
the basis of ongoing protocols aimed at assessing the feasibil-
ity (and efficacy) of Treg infusion alone (ClinicalTrials.gov
Identifier: NCT01911039) or in combination with sirolimus
(ClinicalTrials.gov Identifier: NCT01903473) or low-dose IL-
2 (ClinicalTrials.gov Identifier: NCT01937468) in patients
with steroid-refractory chronic GVHD.
Conclusions
A number of promising approaches are being evaluated for
their potential role in GVHD prophylaxis or treatment. These
approaches are focused on depleting alloreactive donor T-cells
(alemtuzumab, post-transplant cyclophosphamide) or modu-
lating donor T-cell responses against the recipients (sirolimus,
MSC, Tregs, IL-2, bortezomib, azacitidine). With results of
phase 2 studies being promising, large multicenter
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randomized studies are needed to help better defining their
optimal role in GVHD prevention and/or treatment.
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